Aakash Desai, Associate Director, Phase 1 and Precision Oncology Program at UAB O’Neal Comprehensive Cancer Center, shared a post on X about a paper by Melissa L. Johnson et al. published in the Journal of Clinical Oncology:
“Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non–Small Cell Lung Cancer.”
Title: Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
Authors: Melissa L. Johnson, Egbert F. Smit, Enriqueta Felip, Suresh S. Ramalingam, Myung-Ju Ahn, Anne Tsao, Bruce E. Johnson, Michael Offin, Maen Hussein, Ibiayi Dagogo-Jack, Jonathan W. Goldman, Jeffrey M. Clarke, Marcelo V. Negrao, Rachel E. Sanborn, Daniel Morgensztern, Tiziana Usari, Keith Wilner, Linh Alejandro, Nada Rifi, Xiaosong Zhang, and Gregory J. Riely
You can read the Full Article in the Journal of Clinical Oncology.
More posts featuring Aakash Desai.